Acrivon bags a megaround to ad­vance an old Eli Lil­ly pro­gram, 5 months af­ter launch. Is an IPO far be­hind?

Not five months af­ter launch­ing with an old Eli Lil­ly as­set, Acrivon Ther­a­peu­tics is al­ready up­ping the ante.

The Cam­bridge, MA-based biotech pulled in $100 mil­lion in a new Se­ries B, aim­ing to fur­ther ad­vance its lead as­set and com­pan­ion plat­form. And the com­pa­ny has re­cruit­ed some blue-chip back­ers for the raise as RA Cap­i­tal Man­age­ment and Per­cep­tive Ad­vi­sors both par­tic­i­pat­ed in the round.

Does that mean an IPO is on the hori­zon? CEO Pe­ter Blume-Jensen won’t rule it out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER